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Abstract
Rationale Both psychotropic drugs and mental disorders
have typical signatures in quantitative electroencephalogra-
phy (EEG). Previous studies found that some psychotropic
drugs had EEG effects opposite to the EEG effects of the
mental disorders treated with these drugs (key–lock
principle).
Objectives We performed a placebo-controlled pharmaco-
EEG study on two conventional antipsychotics (chlorprom-
azine and haloperidol) and four atypical antipsychotics
(olanzapine, perospirone, quetiapine, and risperidone) in
healthy volunteers. We investigated differences between
conventional and atypical drug effects and whether the drug
effects were compatible with the key–lock principle.
Methods Fourteen subjects underwent seven EEG record-
ing sessions, one for each drug (dosage equivalent of 1 mg
haloperidol). In a time-domain analysis, we quantified the
EEG by identifying clusters of transiently stable EEG
topographies (microstates). Frequency-domain analysis
used absolute power across electrodes and the location of
the center of gravity (centroid) of the spatial distribution of
power in different frequency bands.
Results Perospirone increased duration of a microstate class
typically shortened in schizophrenics. Haloperidol in-
creased mean microstate duration of all classes, increased
alpha 1 and beta 1 power, and tended to shift the beta 1
centroid posterior. Quetiapine decreased alpha 1 power and
shifted the centroid anterior in both alpha bands. Olanza-
pine shifted the centroid anterior in alpha 2 and beta 1.
Conclusions The increased microstate duration under per-
ospirone and haloperidol was opposite to effects previously
reported in schizophrenic patients, suggesting a key–lock
mechanism. The opposite centroid changes induced by
olanzapine and quetiapine compared to haloperidol might
characterize the difference between conventional and
atypical antipsychotics.
Keywords Pharmaco-EEG .Microstates . Schizophrenia .
Key–lock principle . Chlorpromazine . Haloperidol .
Olanzapine . Perospirone . Quetiapine . Risperidone
Introduction
Electroencephalography (EEG) offers high sensitivity to
alterations of human functional brain states (Ozaki and
Lehmann 2000). Specific EEG patterns related to various
psychotropic drugs (Itil 1961; Fink 1968; Saito et al. 1983,
1993, 1998; Saletu 1987; Saletu et al. 1987; Galderisi et al.
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1996, see Mucci et al. (2006) for a review) and mental
disorders (Itil et al. 1972; Saletu 1980; Saletu et al. 1986;
Pascual-Marqui et al. 1999, see Hughes and John 1999 for
a review) were previously reported. Saletu et al. (2002)
investigated the relationship between alternations induced
by mental disorders and by psychotropic drugs using an
EEG source analysis called low-resolution brain electro-
magnetic tomography (LORETA; Pascual-Marqui et al.
1994, 1999). They found that some psychotropic drugs had
EEG effects that seemed to counteract EEG changes that
were seen in mental disorders, (i.e., schizophrenia and
generalized anxiety disorder; this phenomenon has been
termed ‘key–lock principle’; Saletu-Zyhlarz et al. 2000;
Saletu et al. 2002).
A compatibility or incompatibility with the key–lock
hypothesis does not necessarily have implications for the
efficiency of the drug but rather for the potential mecha-
nisms of action. A key–lock pattern of drug response
suggests that the drug acts upon processes that are present
both in patients and controls, but in patients, these
processes are quantitatively abnormal and thus dysfunc-
tional. If a drug does have an antipsychotic effect but shows
other than key–lock patterns of drug responses, it suggests
that the drug affects processes that are qualitatively
different or selectively present only in the responding
patient group. The key–lock principle is thus not a
conclusive approach to predict an antipsychotic action but
is an incomplete but commonly accepted and testable
general scheme to classify drug actions. However, as the
clinical effects of the antipsychotic drugs often occur much
later than the EEG drug effects and may involve mediating
processes, the application of this scheme cannot be easily
extended to the clinical symptoms.
In this paper, we investigated the EEG profile of six
antipsychotic drugs: two conventional antipsychotic drugs
and four new antipsychotic drugs, so-called ‘atypical
antipsychotic drugs’. Atypical antipsychotics are less
specific for D2 receptors but also affect, among others,
5-HT2A receptors and have fewer extrapyramidal side
effects compared to conventional antipsychotic drugs (Stahl
2000). This study investigated how the effects of these
drugs on the EEG of healthy controls compared to the EEG
correlates of schizophrenia and whether conventional and
atypical antipsychotic drugs had different EEG profiles.
EEG data represent a mixture of brain states, and
psychotropic drugs might not affect all of them similarly.
Therefore, these states need to be separated before drug
effects can be studied effectively. Then, the drug effects
may become apparent as alterations in energy, occurrence,
or duration or as changes in the scalp distribution (EEG
generators) of these EEG states. The most commonly used
method to separate EEG states is by frequency transforma-
tion. The different frequency bands identified in EEG have
been closely linked to many specific functional states such
as sleep (Borbely and Achermann 1999) or development
(John et al. 1980). An alternative and complementary
approach is microstate analysis, where the time-domain
EEG is parsed into sub-second periods of quasi-stable field
topography (Lehmann et al. 1987). As in resting EEG,
microstate topographies tend to concentrate around a small
number of prototypical configurations; they can be effi-
ciently clustered, and subsequent statistics can be done
depending on the cluster membership of the microstates
(Koenig et al. 1999, 2002; Strelets et al. 2003; Lehmann et
al. 2005; Mueller et al. 2005).
To assess frequency domain drug effects, we used the
root mean square (RMS) of spectral amplitude across
electrodes as measure of global energy of the different
frequency bands and the scalp location of the center of
gravity of the power-maps to assess the spatial distribution.
Microstate analysis was based on the duration, occurrence,
and total time covered by the different microstate clusters
and on global comparisons of the topography of the
different microstate clusters between drug conditions.
We expected that in the measured quantitative EEG
features, antipsychotic drugs had effects opposite to those
seen in psychotic patients. Furthermore, we expected that
some of these features would be different between typical
and atypical antipsychotic drugs.
Materials and methods
Ethical considerations
This study was conducted in accordance with the Declaration
of Helsinki (1964), and approved by the institutional ethical
review board of Osaka Pharmacology Research Clinic,
Osaka, Japan. All subjects participated voluntarily after being
fully informed about the study and having given their written
consents. Each subject was paid JPY 306,900 (equivalent to
approximately 2700.00 USD) for the entire experiment.
Subjects
Fourteen right-handed, healthy male volunteers participated in
this study. Subjects were recruited by the Osaka Clinical
Research Organization for Medicaments (OCROM), where
the subjects had voluntarily applied to participate in drug
studies. The mean age was 24.1±4.1 years (range 20–
33 years). All subjects were in good health and showed
normal findings in a general and neurological investigation.
They did not have a drug allergy so far. Laboratory
investigation (clinical chemistry, prolactin, blood cell count,
virology for hepatitis B, C and syphilis, and urinalysis) and
electrocardiography showed normal findings. They had no
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brain organic abnormality according to a screening EEG.
Apart from excluding cases with pathological EEGs, subjects
were not selected based on EEG features. An interview
performed by an experienced psychiatrist showed neither
noticeable psychopathological symptoms nor a positive
personal history for psychiatric disorders or substance abuse.
No subjects had participated in drug studies within 4 months
before the start of the study. They had not taken any drug
within a week before entering the study and had not taken any
drug that affects the central nervous system a month before
entering the study. They entered the Osaka Pharmacology
Research Clinic at 18:30 on the day before recording and
stayed there until the morning after the recording day. They
were only allowed to eat what was served at the clinic. Drinks
containing alcohol, xanthine, and grapefruit as well as
smoking were not allowed until all EEG recordings and
physical examinations had been finished.
Thirteen subjects were smokers; average number of
cigarettes smoked per day was 15.8 (SD, 4.5). These
subjects might thus have experienced smoking withdrawal.
However, because the design of the study (see below)
counteracted effects of smoking abstention: (a) comparisons
were made against a placebo baseline (assumingly produc-
ing the same abstention effects), (b) recordings were 2 to
3 weeks apart (preventing a habituation to the abstention),
and (c) drug conditions (including placebo) were counter-
balanced, eliminating possible sequential effects.
Study design
This study was designed as a single-blind, placebo-con-
trolled study. All subjects went through seven EEG
recording sessions separated each by a 2- or 3-week interval.
One of the following substances was applied orally in
each session: chlorpromazine (50 mg), haloperidol (1 mg),
olanzapine (1.25 mg), perospirone (4 mg; Kato et al. 1990;
de Paulis 2002; Shiwa et al. 2003), quetiapine (33 mg),
risperidone (0.5 mg), and placebo. Chlorpromazine and
haloperidol are typical antipsychotics, and olanzapine,
perospirone, quetiapine, and risperidone are atypicals (Stahl
2000). Perospirone has been approved only in Japan. Its
primary mode of action is through an antagonism of 5-
HT2A receptors and D2 receptors; besides, it acts as an
agonist of 5-HT1A receptors (Kato et al. 1990; de Paulis
2002; Shiwa et al. 2003). Dosage was equivalent to of 1 mg
haloperidol, which, according to previous pharmaco-EEG
studies of our laboratory, was enough to have an effect on
the brain electrical activity while assuring subject’s safety
(Saito et al. 1983, 1993, 1998). Powders of test drugs were
capsulated at the Kansai Medical University Hospital’s
Pharmacy. The controller of this study, Noriko Mochizuki,
pharmacist of Osaka Pharmacology Research Clinic,
confirmed undistinctiveness of the test drugs and ordered
them in a crossover, Latin square design. Subjects took the
test drug with 150 ml of water at between 10:00 and 11:00,
after a light meal.
EEG recording
Spontaneous resting EEG was recorded 2 h before the drug
administration and at 2, 4, and 6 h after drug administration in
each session. EEG was recorded from 19 scalp electrodes
placed according to the International 10-20 system (Fp1, Fp2,
F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1,
and O2) referred to linked earlobes. The EEG was amplified
(0.3 to 60 Hz bandpass filter), digitized (128 Hz), and stored
on hard disk using an EEG-1100 NIHON KODEN system
(Nihon Koden, Tokyo, Japan). After each EEG recording,
subjects were asked for the presence of side effects, which
were then classified into slight, moderate, or severe sleepi-
ness, fatigue, lassitude, and nausea. Furthermore, clinical
chemistry, prolactin, and blood cell count were assessed.
Quantitative EEG analysis
From the stored EEG data, the first ten artifact-free 2-s
epochs were selected. The selected data epochs were
recomputed against average reference. For the following
analyses, we used Brain Analyzer (version 1.05, Brain
Products GmbH, Munich, Germany). EEG data recorded
before drug administration was considered as habituation
for recording of EEG and excluded from analysis.
EEG microstate analysis
For microstate analysis (Koenig et al. 1999, 2002), the data
was digitally band-pass filtered from 2 to 20 Hz. Global
field power (GFP; Lehmann and Skrandies 1980), which
quantifies the overall potential variance across the set of
electrodes, was computed at each moment in time. As
topography remains stable around peaks of GFP and
changes during the troughs, only topographies at momen-
tary maxima of the GFP were further analyzed (Lehmann et
al. 1987; Strik and Lehmann 1993; Wackermann et al.
1993). As in previous works (Koenig et al. 1999, 2002;
Strelets et al. 2003; Lehmann et al. 2005; Mueller et al.
2005), four optimally fitted microstate class topographies
were obtained from all data of EEG using a modified
version of the k-mean clustering algorithm (Pascual-Marqui
et al. 1995). The algorithm was instructed to seek four
classes of microstate topography and to assign each
topography of EEG to one of these classes. The clustering
criterion was global map dissimilarity (Lehmann and
Skrandies 1980) between the original maps, disregarding
map polarity. This number of classes has previously been
found to be optimal using a cross validation criterion and
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was maintained to preserve comparability with earlier
studies. Microstate class topographies were computed
individually and averaged across subjects and time points
using a permutation algorithm that maximized the common
variance over subjects and time points (Koenig et al. 1999).
Within each epoch, microstates were identified as contin-
uous epochs where all topographies were assigned to the
same class. Individual microstate profiles were computed
for each class, consisting of mean microstate duration
(duration), mean number of microstates per second (occur-
rence), and percentage of total analysis time occupied in
that state (contribution). We calculated these values over all
subjects and all time points after drug administration.
EEG frequency domain analysis (EEG global spectral
amplitudes and spatial centroids)
All selected EEG epochs were frequency-transformed using
the fast Fourier transformation. Spectral amplitudes were
averaged across epochs for each electrode, subject, and
condition. The RMS of spectral amplitude was computed
across electrodes to obtain a measure of global amplitude
for each frequency. The spatial configuration of each
spectral amplitude map was quantified by computing the
location of the center of gravity or ‘centroids’ (Wackermann
et al. 1993) of the spectral amplitudes. Independently of
total amplitude, these frequency domain map centroids
reduce spectral distributions to two spatial parameters: the
co-ordinate values of the location of the centroid on the
anterior–posterior and on the left–right axes. As measuring
units, electrode gridline distances (ED) were used, where
one ED was the distance between two 10% lines of the
modified 10-20 system (Fig. 1).
For each subject and condition, RMS and centroid
locations were averaged within the following frequency
bands: delta (1.5–6.0 Hz), theta (6.5–8.0 Hz), alpha 1 (8.5–
10.0 Hz), alpha 2 (10.5–12.0 Hz), beta 1 (12.5–18.0 Hz),
beta 2 (18.5–21.0 Hz), and beta3 (21.5–30.0 Hz). These
frequency bands have previously been identified by factor
analysis (Kubicki et al. 1979).
Statistics
EEG microstate analysis
Microstate configuration Separately for each of the four
microstate classes, the configurations of their mean to-
pographies over subjects and timepoints for each drug were
compared between each antipsychotic drug and placebo
using a randomization test (Manly 1991) based on the
dissimilarity of topographies (Lehmann and Skrandies
1980). This randomization statistics used in this paper has
been called topographic analysis of valiance and has
previously been extensively described and applied to EEG
and event-related potential topographies (Strik et al. 1998). It
estimates the probability that the observed difference
between two mean topographies can be obtained by chance.
(For a detailed description, see Strik et al. 1998.)
Microstate profiles For each microstate value (duration,
occurrence, and contribution), repeated three-way analyses
of variance (ANOVAs) were performed (7 drugs×3 time
points×4 microstate classes). When there were significant
( p<0.05) main effects or interactions including drug, we
computed post hoc repeated three-way ANOVAs (2 drugs×
3 time points×4 microstate classes) comparing each
antipsychotic drug separately with placebo. Significant
drug effects in these post hoc ANOVAs were further
explored using paired t tests.
EEG frequency domain analysis (EEG global spectral
amplitudes and spatial centroids) Repeated two-way
ANOVAs (7 drugs×3 time points) were computed for
RMS and for the anterior–posterior and left–right positions
of the centroid locations in each frequency band. When
significant (p<0.05) or weak (p<0.1) drug effects appeared,
post hoc repeated two-way ANOVAs (2 drugs×3 time
points) were performed comparing each antipsychotic drug
separately to placebo.
Fig. 1 Example for the quantification of the spatial distribution of
spectral amplitude. Head seen from above, left ear left. Tick marks at the
coordinate axes indicate electrode numbers, in the anterior–posterior
direction (vertical axis) and in the left–right direction (horizontal axis).
A sample distribution of spectral amplitudes is shown, darker values
indicate more amplitude. The location of the centroid is indicated by the
white cross. The configuration of the map is described by the anterior–
posterior and left–right coordinates of the centroid
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Results
All subjects went through all recording sessions without
severe adverse drug reactions. Reported non-severe adverse
drug reactions of antipsychotic drugs by subjects were
slight sleepiness (during 39.3% of all EEG recordings),
moderate sleepiness (9.5%), slight general fatigue (2.4%),
moderate general fatigue (1.2%), slight lassitude of the
upper limbs (1.2%), moderate general lassitude (1.2%),
slight nausea (1.2%), slight increase in plasma concentra-
tion of prolactin (19.0%), and slight increase in white blood
cells (1.2%). We confirmed that all these adverse drug
reactions disappeared in a reexamination.
Microstate analysis
Microstate configuration
Across the sample of 392 (14 subjects×7 drugs×3 time
points) sets of EEG epochs, four microstate classes accounted
on the average for 75.8% of the variance (SD=7.2%).
Figure 2 shows the mean topographies of the four microstate
classes obtained from all EEG data and the percent total
time covered by each state. These overall results closely
replicated previous work (Koenig et al. 1999, 2002; Strelets
et al. 2003; Lehmann et al. 2005; Mueller et al. 2005) and
were therefore labeled and arranged in the same order as in
previous publications (Koenig et al. 1999, 2002). Micro-
states of class A had a left occipital to right frontal orientation,
class B was from right occipital to left frontal, class C had a
symmetric occipital to prefrontal orientation, and class D was
also symmetric but with a frontocentral and an occipital
maximum of absolute voltage.
Figure 3 shows the configurations of four microstate
classes (A–D) obtained from EEG data after each drug.
Haloperidol, quetiapine, and risperidone significantly
changed configurations of all four classes. Perospirone
significantly changed configurations of three classes (A, C,
and D). Chlorpromazine significantly changed configura-
tions of two classes (C and D). Olanzapine significantly
changed configurations of only class C. Visual inspection
indicated that many, but not all of these changes of
microstate class topography, could be regarded as a
clockwise rotation of the axis connecting the electrodes
with the maximum and the minimum voltage.
Microstate profiles
Microstate duration Microstate duration varied between
64.42 and 77.50 ms for all drugs and four microstate classes.
Repeated three-way ANOVAs (7 drugs×3 time points×4
microstate classes) showed a significant main effect of drug
(F=3.27; df=6.78; p=0.0064). Repeated three-way
ANOVAs between each antipsychotic drug and placebo
yielded a significant main effect of drug between haloperidol
and placebo (F=6.99; df=1.13; p=0.02), namely, the mean
duration of all four microstate classes was significantly
increased after haloperidol compared to placebo. Similarly,
chlorpromazine had a tendency to increase the mean duration
of all four microstate classes compared to placebo (F=4.17;
df=1.13; p=0.0619). Figure 4a shows the difference of
mean duration of the four classes between each antipsy-
chotic drug and placebo. There was a significant
interaction between drug and microstate class (F=3.16;
df=3.39; p=0.0354) when comparing perospirone and
placebo. Post hoc paired t tests identified a significant
( p=0.0314) increase in duration of class D after perospir-
one (76.01 ms) compared to placebo (70.77 ms; Fig. 4b).
Microstate occurrence Microstate occurrence varied be-
tween 3.20 and 3.94 counts/s for all drugs and four microstate
classes. Repeated three-way ANOVAs (7 drugs×3 time
points×4 microstate classes) showed a significant effect of
drug (F=3.07; df=6.78; p=0.0095). Repeated three-way
ANOVAs between each antipsychotic drug and placebo
identified a significant main effect of drug between
haloperidol and placebo (F=5.93; df=1.13; p=0.03), that
Fig. 2 Spatial configuration of four microstate classes (A–D) over all
subjects and time points (maps in the lower part) and the contribution
of each microstate class to the total analysis period (upper graph). The
maps are shown as normalized isopotential maps, head seen from
above, nose up. White and black map areas indicate opposite polarity
against average reference. The dots in the upper graph indicate the
contribution of each microstate class to the total analysis period
(vertical axis) as function of microstate class (horizontal axis). The
vertical bars are the 95% confidence interval. The horizontal arrows
with two stars indicate significant (p<0.05) differences of contribution
between microstate classes
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is, the mean occurrence of microstates was significantly
decreased after haloperidol compared to placebo. Figure 4c
shows the difference of mean occurrence of the four classes
between each antipsychotic drug and placebo.
Microstate contribution Microstate contribution varied be-
tween 21.0 and 28.5% for all drugs and 4 microstate classes.
Repeated three-way ANOVAs (7 drugs×3 time points×4
microstate classes) yielded a main effect of microstate class
(F=12.92; df=3.39; p<0.0001; Fig. 2) and an interaction
between microstate class, time, and drug. However, the post
hoc repeated three-way ANOVAs comparing each drug to
placebo failed to show significant effects including drug.
EEG frequency domain analysis
EEG power analysis
The overall ANOVAs on RMS yielded significant drug
effects in the alpha 1 band (F=4.3; df=6.78; p=0.0009) and
a weaker drug effect in the beta 1 band (F=2.07; df=6.78;
p=0.0654). Post hoc tests indicated that haloperidol increased
RMS in the alpha 1 (F=5.66; df=1.13; p=0.0334) and beta 1
(F=6.28; df=1.13; p=0.0263) band compared to placebo.
Quetiapine significantly decreased RMS in the alpha 1 band
compared to placebo (F=6.22; df=1.13; p=0.0269; Fig. 5a).
Gravity center of EEG
The anterior–posterior centroid location showed significant
drug effects in the alpha 2 band (F=2.96; df=6.78; p=
0.0118) and weak drug effects in alpha 1 (F=1.92;
df=6.78; p=0.0879), beta 1 (F=1.98; df=6.78; p=0.078),
and beta 2 (F=2.09; df=6.78; p=0.0635) bands. Post hoc
tests indicated that quetiapine shifted the centroid anterior
in both alpha bands (alpha 1, F=751.42, df=1.13,
p<0.0001; alpha 2, F=16.32, df=1.13, p=0.014; Fig. 5b,c).
A more anterior centroid location was also observed after
olanzapine compared to placebo in alpha 2 (F=22.4;
df=1.13; p=0.0003) and beta 1 (F=4.68; df=1.13;
p=0.0498; Fig. 5c,d). On the other hand, haloperidol,
Fig. 3 Configurations of the four microstate classes (A–D) over all
subjects and time points separately for each drug. Map display as in
Fig. 2. Two stars indicate a significant (p<0.05) difference between an
antipsychotic drug and placebo in a microstate class, one star indicates
a tendency (p<0.1)
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compared to placebo, tended to shift the centroid posterior
in the beta 1 band (F=3.38; df=1.13; p=0.0888; Fig. 5d).
No effects were observed on the left–right axis.
Discussion
We performed a study of pharmaco-EEG under two
conventional antipsychotic drugs and four atypical antipsy-
chotic drugs taken by healthy volunteers. The EEG was
quantified by EEG microstate analysis, by total spectral
amplitude, and by the location of the spatial gravity center
of spectral amplitude. These methods yielded consistent
differences between conventional and atypical antipsychot-
ic drugs. Some of these effects were opposite to the
abnormalities seen in schizophrenic patients and compati-
ble the key–lock principle (Saletu-Zyhlarz et al. 2000;
Saletu et al. 2002).
The analysis of EEG microstates was based on four
classes of microstates constructed from all the measured
EEG data. The contribution of each microstate class was
similar to the previous studies that investigated mentally
healthy subjects (Koenig et al. 2002).
All antipsychotic drugs we used in this study signifi-
cantly affected the spatial configuration of some of the
microstate classes. This means that the antipsychotic drugs
changed the configuration of determined, transiently active
neural networks. Particularly, all antipsychotic drugs affect-
ed class D. Microstate topographies have previously been
shown to be abnormal in patients with schizophrenia
selectively for class D (Koenig et al. 1999), suggesting
that the drugs have a selective effect on brain states altered
in schizophrenia.
Perospirone and haloperidol increased microstate dura-
tion compared to placebo. Perospirone selectively increased
the duration of class D, while haloperidol increased the
mean duration of all four microstate classes. In addition,
chlorpromazine had a tendency to increase the mean
duration of all four microstate classes compared to placebo.
Previous studies on schizophrenic patients showed signif-
icant decrease in microstate duration of class B (Strelets et
al. 2003; Lehmann et al. 2005) and D (Koenig et al. 1999;
Lehmann et al. 2005) and a tendency toward decrease in
mean microstate duration of all four microstate classes
(Strelets et al. 2003; Lehmann et al. 2005) compared to
control subjects. Lehmann et al. (2005) interpreted the
decrease in microstate duration as a result of precocious
termination of information processing in certain classes of
mental operations.
Increased mean duration of all microstate classes was
observed only after the conventional antipsychotic drugs
haloperidol and chlorpromazine, which were both D2
receptor antagonists. The increase in mean microstate
duration across microstate classes by conventional antipsy-
chotic drugs may thus result from a blockade of D2
receptors. Longer duration of class D has been associated
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Fig. 4 Difference between each drug and placebo in mean microstate
duration and occurrence. a Mean differences of microstate duration for
the different drugs against placebo. Zero indicates the placebo level.
The dots indicate mean values; the vertical bars indicate the standard
deviation. Two stars indicate a significant ( p<0.05) difference
between an antipsychotic drug and placebo in the mean microstate
duration across classes; one star indicates a tendency ( p<0.1). b The
mean microstate duration of perospirone (open squares) and placebo
(filled circles) separately for each microstate class. Again, the vertical
bars indicate the standard deviation. Perospirone significantly in-
creased the duration of class D compared to placebo. c The differences
between drugs and placebo of mean microstate occurrence per second
across the four microstate classes can be seen. The dots indicate mean
values; the vertical bars indicate the standard deviation. Significance
indicated as in previous figures
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with less paranoid symptoms in schizophrenic patients
(Koenig et al. 1999). Therefore, we can speculate (and
eventually test) that the selective increase in duration of
class D after perospirone has a particular effect against
paranoid symptoms.
The employed drugs thus changed properties of transient
brain electric states, and these changes depended consistent-
ly on the type of drug employed. Although the biological
mechanism relating the drug’s molecular actions to the
microstate effects remains unknown, it became apparent that
haloperidol, chlorpromazine, and perospirone acted differ-
ently upon EEG microstates from the other employed drugs.
This diversity in microstate changes after intake of a
neuroleptic drug in controls may thus correspond to the
diversity observed in patients’ responses to those drugs,
which may be based on a diversity of biological mechanisms
in schizophrenia, and these microstate changes may be
compatible with the key–lock principle.
Itil (1961) proposed to classify psychotropic drugs by
their profile of EEG spectral power changes. He classified
antipsychotic drugs into a ‘major neuroleptic type’ and a
‘major tranquilizer type’. The major neuroleptic type was
characterized by an increase in slow and alpha waves. The
major tranquilizer type was characterized by an increase in
slow waves and a decrease in alpha and fast waves. Later,
Saletu et al. (1987) classified antipsychotic drugs into ‘non-
sedative neuroleptics’ and ‘sedative neuroleptics’ also
based on spectral power analysis. Non-sedative neuroleptics
were determined by increased alpha and alpha-adjacent beta
1 activity. Sedative neuroleptics were characterized by
increased delta and theta activity, decreased alpha and, less
consistently, increased concomitant fast beta activity. In this
Fig. 5 Frequency domain drug effects. a The mean RMS of spectral
amplitude of haloperidol, quetiapine, and placebo in seven frequency
bands over all subjects and time points. The vertical bars indicate
standard deviation. b–d The mean locations of spatial centroid of the
spectral amplitude distribution of the different drugs and placebo in
alpha 1, alpha 2, and beta 1 bands. The inset in b indicates
the position, extent, and orientation of the area shown in b–d. The
continuous lines indicate the centroid positions under placebo, the
dotted lines and the arrows indicate drug-induced changes in centroid
position with a significance level below 10%
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study, haloperidol increased RMS in alpha 1 and beta 1
band compared to placebo. This profile of haloperidol
matched the characteristics of the major neuroleptic type
and of the non-sedative neuroleptics. Slow alpha has been
suggested to indicate a resting state (Isotani et al. 2001).
Haloperidol may therefore enhance brain functions typical-
ly observed during awake resting. Quetiapine induced a
decrease in alpha 1 power compared to placebo. This
feature corresponds to Itil’s major neuroleptic type and the
Saletu’s sedative neuroleptics, and it may suggest that
quetiapine has a strong sedative effect.
Previous quantitative EEG comparing schizophrenic
patients to healthy controls showed that patients had a
decrease in activity in alpha 1 and an increase in activity
and mean frequency in the beta band (Itil et al. 1972; Saletu
1980; Saletu et al. 1986). Our effects of haloperidol in
healthy controls may be considered to be opposite to these
results, because an increase in beta 1 (slow beta) power can
be interpreted as decrease in mean frequency of the beta
band. This phenomenon may thus be compatible with the
key–lock principle.
Compared to placebo, quetiapine and olanzapine shifted
the centroid anterior, quetiapine in both alpha bands and
olanzapine in the alpha 2 and beta 1 band. The olanzapine
results confirm a study by Hubl et al. (2001), who reported
that olanzapine induced a frontal shift of electrical brain
activity, significant in beta 2 (16.0–19.5 Hz) and a trend
and in alpha 2 (10.0–11.5 Hz). The olanzapine effects in the
beta 2 band were also similar to the results reported for
clozapine, the prototype of an atypical antipsychotic drug
(Galderisi et al. 1996). The EEG anteriorization induced by
olanzapine and quetiapine may be related to effects of
atypical antipsychotic drugs on frontal brain regions:
atypical antipsychotics have a better effect on negative
symptoms, which are considered as frontal lobe dysfunc-
tion. Furthermore, compared to the typical antipsychotics,
they have an antagonistic action on 5-HT2A receptors,
which also affect frontal lobe functions.
Haloperidol was the only drug to shift alpha and beta
band centroids posterior, although this was only a tendency
in the beta 1 band (Fig. 4b–d). The observation that
haloperidol had effects on centroid location opposite to
other antipsychotic drugs may be because haloperidol
antagonizes D2 receptors more than atypical antipsychotics
(Farde et al. 1992; Kasper et al. 2002). Dierks et al. (1995)
reported a significant anteriorization of the EEG in
schizophrenics compared to normals in beta 1 (12.0–
15.5 Hz) and beta 2 (16.0–19.5 Hz) using an equivalent
single dipole model (Lehmann and Michel 1989). This
result is opposite to the anterior shift of haloperidol in this
study. The strong antipsychotic effects of haloperidol may
thus again be based on some key–lock mechanism,
although the potential extrapyramidal side effects of
haloperidol suggest some mismatch between the patho-
physiological states of the patients and the counteracting
drug effects.
Chlorpromazine and risperidone did not yield any
significant result. This may be due to the low dosage of
the test drugs or because these drugs specifically affect some
abnormal brain functions usually not present in healthy
controls. Compared to other studies, the dosage of the test
drugs in this study was low, so it is difficult to compare these
results with the results of other studies. For chlorpromazine
and risperidone, it would thus be interesting to know
whether in healthy controls, there is a dose–response relation
and whether the dose used in this study was below the
response threshold. In addition, it would be interesting to
establish the EEG effects of different antipsychotic drugs on
patients with schizophrenia and the relation of drug-related
EEG changes with the clinical response.
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